To explored whether GINS1 participated in sorafenib resistance in HCC, HepG2, and Huh7 cells without or with (w/o) GINS1 deletion by shGINS1-2 were treated with increased doses of sorafenib. The gene discussed is GINS1; the disease is hepatocellular carcinoma.